Moreover, the small-molecule c-Myc inhibitor, 10058-F4, was reported to be effective in anti-cancer treatment, such as for leukemia [107], hepatocellular carcinoma [103], and prostate cancer [100]. Here, MYC is linked to prostate carcinoma.